The Murky Waters of Method Validation
A field seeks clarity on validation in preclinical studies Continue reading
Leveling the Biological Playing Field
After years of debate, the FDA is poised to approve its first biosimilar. What comes next? Continue reading
Spoilt for Choice
There’s no shortage of ways to analyze a monoclonal. Now, for the hard part. Continue reading